Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) shares saw an uptick in trading volume on Wednesday . One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Following the completion of the transaction, the insider directly owned 93,969 shares of the company’s stock, valued at $3,334,959.81. Insiders sold a total of 178,322 shares of company stock valued at $5,969,286 in the last 90 days. Pharvaris Company Profile(Get Free Report)Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases.